Engineered exosomes as carriers for chemotherapeutic drugs and targeted RNA demonstrate potential for treating pancreatic cancer and its metastasis, including strategies targeting KRAS gene mutations, offering new directions for therapy. Here, KRAS is linked to familial pancreatic carcinoma.